Blue Horseshoe Stocks: NBEV Update & More

New Age Beverages Corp. NBEV

The performance of NBEV has been absolutely incredible this week, and we’ve been sticking with it the whole way. We were just mentioning yesterday morning how the stock set its all time single session record move on Wednesday, and yesterday set another new all time high for the second day in a row!

NBEV traded in a range from 5.27 to 7.85 (+49%) which also marked a total rise of 423% over our observed low of 1.50 following our initial alert on the 4th of this month. In post-market trading activity, the stock actually reached 10.34, which extends that figure to a gain of 589% in a matter of just twelve trading days!

With NBEV firmly in Blue Sky territory, there’s no telling where this ride will let off, but in and of itself, the performance exhibited by this play in recent weeks has been nothing short of amazing.
_____

Altimmune, Inc. ALT

Speaking of September 4th, that was also the morning that we tagged ALT for observation, and despit a very slow start to the month, this stock has absolutely exploded this week as well, even more so than NBEV.

ALT has traded in an absolutely mammoth intraweek range from a low of 4.27 to yesterday’s new high of 36.25. That’s an upswing amounting to 749% The fact that we’ve routinely come up with big board plays that blow their lids shows that while we’ve come a long way from the days of our focusing solely on penny stocks, we are still more than capable of identifying movers on the upper exchanges that are just as impressive!


SPDR S&P 500 ETF (SPY) – Recap 

Our fresh options trading idea for the SPY yesterday also bore fruit- after we signaled the SPY Weekly $291.50-292.50 Calls, all three contracts produced significant chances for traders to net a solid intraday profit.

We’ve traditionally been very good at playing the SPY options chain and this time was no different. The total possible intraday gains were:

$91 Calls – Range: .95-2.40 – Max Gain: 153%
$92 Calls – Range: .71-1.92 – Max Gain: 170%
$93 Calls – Range: .46-1.42 – Max Gain: 209%
_____

Fresh Options Idea:
Micron Technology, Inc. MU Weekly $43-45 Calls*

*Do NOT attempt to trade weekly options on Friday’s unless you are an expert level trader with disposable funds.


Extended Watchlist: 
ADT, IGXT, LCI, AWSM, ACAD, SDRL, ADBE

Blue Horseshoe Stocks: SAGD Review & More

South American Gold Corp. SAGD
(soon to be Sativa Growth International)

On the morning of last Thursday the 21st, we signaled our interest in tracking SAGD, and at the time the stock was trading as low as .0135. In the week of trading which has followed, the stock has made a very nice move.

Yesterday, SAGD hit a new high of .0364 which represents a one-week upswing of 170% and continues our recent impressive trend of identifying not only hot options plays, but scoring big with stocks as well.

We should also mention that the company announced its plans to change its name and official focus to reflect the work it has been doing to move toward the cannabis space.(>>Read PR) It’s one of our favorite OTC market sectors, and we’ll be tracking SAGD as part of it moving forward.


Accenture plc. ACN – Recap

Speaking of success in options ideas, our fresh play from yesterday morning’s premarket report yielded fantastic single-session results. We designated the ACN Weekly $157.50-162.50 Calls as our go-to options play for the day and all three of the contracts contained in our highlighted range were big-time winners on the day.

$157.50 Calls – Range: 2.36-7.41 – Max Gain: 214%
$160 Calls – Range: 1.24-5.60 – Max Gain: 352%
$162.50 Calls – Range: .50-3.10 – Max Gain: 520%
_______

Fresh Options Ideas:
Nike Inc. – NKE Weekly $77-79 Calls
SPDRA S&P 500 ETF – SPY Weekly $270-272 Calls


Extended Watchlist:
IQ, BAC, VRTX, ACAD, DERM, PIR(bottom-watch)

Blue Horseshoe Stocks: TSLA Review & More

Tesla, Inc. TSLA – Recap

Our fresh options idea for the day yesterday morning was a range of puts in the TSLA  chain, on the heels of its poorly-received earnings call. What resulted, as the stock began the session under duress, were some very nice opportunities for us before lunchtime.

Our designated range was the TSLA Weekly $285-277.50 Puts and we happily observed the following solid moves:

$285 Calls – Range: 4.95-10.74 – Max Gain: 117%
$282.50 Calls – Range: 3.92-8.90 – Max Gain: 127%
$280 Calls – Range: 2.94-7.21 – Max Gain: 145%
$277.50 Calls – Range: 2.30-5.78 – Max Gain: 151%



Potential Bottom Plays

Esperion Therapeutics, Inc. ESPR – We like the look of the ESPR chart for a potential extended recovery play. As you can see on the chart the stock has been in quite a bit of trouble over the past few sessions, losing roughly half of its previous value in a matter of just a few days.We’re always looking for heavily oversold stocks in line for the chance at a big rebound.


________

Iconix Brand Group, Inc. ICON – We also want to add this one to our watchlist. The stock has been pushed way down amid an SEC investigation concerning ICON and a famous partner of the company, award-winning recording artist Jay-Z, and his Rocawear brand.

As you can see below, in addition to a more steady backslide that dates back much further, the stock has really gone into free fall in recent sessions, resulting in a scenario that could produce a significant rebound, which we’ll want to be looking for.


Extended Watchlist:
ACAD, FRED, CTRL, CREG, CPHI, SHAK, CNET

Blue Horseshoe Stocks: CNAT Recap & More

Conatus Pharmaceuticals, Inc. CNAT

We were fairly confident that at least one of the pharma news plays we put forth in yesterday’s premarket report would turn out a promising session, and CNAT definitely rose to the occasion.

We highlighted it, of course, because of a big collaboration and licensing deal for one of the company’s drugs, which adds a quick $50M cash to the books almost immediately, and even more down the road.

After gapping up considerably in the premarket, the stock underwent a dip-and-rip scenario which carried it to a daily low of 4.27 before it pushed its way up to a high of 5.50. That marked a solid intraday upswing of 29% and came on four times the three-month average volume.


ACADIA Pharmaceuticals, Inc. ACAD

ACAD was the other play off of our pharma watchlist that provided us with significant opportunities, which were even bigger than the previously mentioned stock.

We offered an options idea, the ACAD Weekly $28-31 Calls, and all but a couple sets of contracts in that range produced respectable intraday moves.

$28 Calls – Range: .70-1.66 – Max Gain: 137%
$28.50 Calls – Range: .59-1.40 – Max Gain: 137%
$29 Calls – Range: .40-.80 – Max Gain: 100%
$29.50 Calls – Range: .30-.70 – Max Gain: 133%
$30 Calls – Range: .18-.50 – Max Gain: 178%

______

NIKE, Inc. NKE – Fresh Options Idea

NKE is coming off a post-market earnings beat yesterday, so we want to enter an idea into the logs for this situation.

We’re going to be monitoring the activity in the NKE Weekly $52.50-54 Calls for possible daytrades and/or swing trades into the end of the week.


Extended Watchlist:
LEOM, MMEG, INO, ESEA, SINO, DCIX, DRYS, HIMX(Bottom-Watch)

Blue Horseshoe Stocks: Pharma News Watchlist & More

Pharma News Watchlist:

We’ve got a trio of pharma plays to add to our watchlist on the heels of fresh news releases for each of them this morning. Each stock is gapping up significantly in the premarket, and we’ll be waiting in the wings once the session commences to see if we can use the resulting activity to our advantage.

Akebia Therapeutics, Inc. AKBA – Per the newly announced agreement out today, AKBA has entered into a Collaboration and License Agreement to carry forward with the development of one of its treatments. The deal comes with an immediate payment of $125M, a cash infusion that represents roughly 40% of the company’s total market cap as of yesterday.

______

ACADIA Pharmaceuticals, Inc. ACAD – In the case of ACAD, we’ve gotten word of positive top-line results in a Phase II study it was conducting on the company’s Alzheimer’s drug.  To leverage the present activity to our advantage here, we’re going to track the ACAD Weekly $28-31 Calls. (>>View PR)

_______

Conatus Pharmaceuticals, Inc. CNAT

Here we have another collaboration and licensing deal, for CNAT’s liver drug, which is going to be bringing a $50M cash infusion Conatus’ way. That’s just the initial tranche, with more payments to follow as outlined in the relevant filing (>>View 8-K)


Globalstar, Inc. GSAT

We put GSAT on watch as a possible momentum play in yesterday morning’s premarket report, and while it didn’t break out in a major way, it did continue the trend of solid upward momentum that has been observed in recent sessions. From an early low of 1.25, the stock ran as high as 1.60; a 28% pop.

The performance, while not astronomical, was certainly enough to hold our interest in continuing to monitor GSAT’s activity moving forward.


Cellectar Biosciences, Inc. CLRB – Reminder

We just wanted to take a quick moment to reiterate a possible bottom-play selection we made last week in the form of CLRB. We’re still tracking this one, and think it has a good chance to produce a recovery, possibly following the holiday break. So we’re going to want to leave a space on our watch screens reserved for CLRB in the days and weeks ahead.


Extended Watchlist:
AXPW, CAPS, MFST, ENDV, ETRM, EXAD